SEC Form 4 · accession 0000925421-17-000363
Krystal Biotech, Inc. · KRYS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Daniel Janney
Director
Period of report
Sep 22, 2017
Accepted (ET)
Sep 25, 2017 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001711279
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Sep 22, 2017 | P | 200,000 | $10.00 | A | 330,590 | I | See footnotes |
| Common StockF1,F2,F3 | Sep 22, 2017 | C | 124,456 | — | A | 455,046 | I | See footnotes |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Convertible Preferred StockF2,F3,F1 | — | Sep 22, 2017 | C | 124,456 | D | — | — | Common Stock | 124,456 | 0 | I |
| Stock Option (Right to Buy) | $2.46 | holding | — | — | — | Nov 10, 2020 | Nov 9, 2026 | Common Stock | 37,894 | 37,894 | D |
Explanation of responses
- F1The Series A convertible preferred stock converted on a one-to-one basis into 124,456 shares of common stock upon the closing of Krystal Biotech, Inc.'s initial public offering.
- F2Directly beneficially owned by Alta Bioequities, L.P.
- F3Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The reporting person is the Managing Director of Alta Bioequities Management, LLC. The reporting person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.